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Abstract: It has been shown that sarcosine suplementation stimulates the proliferation of prostate cells 
and also their invassiveness. In present study we show that enzymes conected with sarcosine 
conversion to glycine (sarcosine dehydrogenase, pipecolic acid oxidase) are stimulated due 
to sarcosine treatment. Further, sarcosine treatment increases S-adenosylmethioneine-to-S-
adenosylhomocysteine ratio, which indicates a release and utilization of free methyl groups 
from sarcosine degradation pathway. We identified the highest induction of global methylation 
in non-malignant PNT1A cells, but global methylation profiles were altered also in malignant (22Rv1) 
and metastatic (LNCaP) cells. The influence on methylation changes was further verified using 
hypomethylating agent 5-azacytidine (5-aza). Co-treatment of prostate cells with 5-aza and sarcosine 
resulted in decrease in cells invassiveness when compared to treatment with sarcosine alone. This 
correlates with sarcosine-related hypermethylation of genes involved in cells growth and cell cycle.
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INTRODUCTION
Sarcosine is an imino acid and a potential biomarker of prostate cancer (PCa). Concentration 
of sarcosine is substantially increased during PCa progression to its metastasis (Sreekumar et al. 
2009). In its biochemical pathway, sarcosine is formed from dimethylglycine by dimethylglycine 
dehydrogenase (DMGHD, EC 1.5.8.4) (Metallo 2012) or from glycine by glycine-N-methyltransferase
(GNMT, EC 2.1.1.20). On the other hand pipecolic acid oxidase (PIPOX, EC 1.5.3.1) or sarcosine 
dehydrogenase (SARDH, EC 1.5.8.32) can demethylate sarcosine to form glycine while providing free 
methyl group to methyl-donor S-adenosylmethionine (SAM), which is further demethylated into 
S-adenosylhomocysteine (SAH) (Dodt et al. 2000). This can be associated with a methylation 
of an acceptor (DNA, RNA, neurotransmitters or lipids). Methylation processes can impact a wide 
array of biological processes, including gene transcription, which could be connected with initiation 
and progression of PCa. For instance, methylation of cytosine-phosphate-guanine dinucleotides 
in promoter can inactivate the genes. Although the connection between epigenetics and cancer are well 
known, there is lack of data regarding the effect of increased amount of sarcosine on methylation 
status of prostate cells (Ianni et al. 2013).
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Three human prostatic cell lines were used for an experiment, representing benign 
and malignant cells: i) the PNT1A human cell line established by immortalization of normal adult 
prostatic epithelial cells by transfection with a plasmid containing SV40 genome with a defective 
replication origin, ii) 22Rv1 which is a human prostate carcinoma epithelial cell line derived 
from axenograft that was serially propagated in mice after castration-induced regression and relapse 
of the parental, androgen-dependent CWR22 xenograft, iii) LNCaP human cell line estabished from 
an androgen-sensitive metastasis located in the left supralavicular lymph node. All cell lines used 
for experiments were purchased from Health Protection Agency Culture Collections (Salisbury, UK). 
Culture conditions and treatment protocols
All cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS)
supplemented by penicillin (100 U/ml) and streptomycin (0.1 mg/ml). The cells were maintained 
at 37 °C in humidified incubator with 5% CO2. The exogenous supplementation with sarcosine 
(10 μM) and azacytidine (10 μM) was initiated after cells reached ~80 % confluence. The cells were 
harvested after 2; 6 ;12 and 24 h for HPLC-MS analysis and scratch test, after 24; 48 and 72 h 
for western blotting, and after 24 h for imunofluorescence. All experiments were designed as five 
biological replicates (n = 5) measured three times at each time point.
Imunofluorescence of sarcosine metabolsim-related enzymes 
For imunofluorescence (IF) were culture cells seded into eight-well chamber slides and after 24 
h of adherence were treated by sarcosine (10 μM) and azacytidine (10 μM). As a control were used 
cells without treating. Cells were fixated after 24 h incubation by 4% formaldehyde, permeabilizated 
by 0.25% Triton X-100, blocked in 5% bovine serum albumin in PBS and imunostained by primary 
antibody overnight in 4 °C. Detection was accomplished using fluorescein isothiocyanate 
(FITC)-conjugated or CruzFluor™ 645 (CFL 645) labeled secondary antibodys. DNA staining 
by Hoechst were used for counter. IF was evaulated by fluorescent microscope for GNMT, SARDH, 
DMGDH, and PIPOX as a enzymes involved in sarcosine metabolism. 
Extraction and quantitation of SAM and SAH
SAM and SAH were extracted in MeOH and acetic acid (80 : 20; v/v). Solvent was added 
to the frozen cells followed by slow thawing on ice. After that, the cells wer snap-freezed in liquid 
nitrogen and thawed on ice again. After three times freez/thaw cycle were samples centrifuged 
at 9000 × g. The supernatant was transfered to 1.5 ml glass vial and washed with solvent. 
The quantitation of SAM and SAH was performed using high-performance liquid chromatography 
with electrospray ionization quadrupole-quadrupole-time-of-flight mass spectrometer 
(HPLC-ESI-QqTOF MS). The samples were separated on C18 reverse phase column. As mobil 
phases, water with 0.1% (v/v) formic acid and methanol with 0.1% (v/v) formic acid were used. 
Global analysis of DNA methylation
The DNA was extracted by the ExtractNow™ DNA Mini Kit and quantified at λ = 260 nm. 
The global methylation was performed using a methylation DNA quantification kit, incubated 
with capture and detection antibodies and read by λ = 450 nm. Quantification of global DNA
methylation was compared to positive control that had been previously fully methylated. 
The methylation level depends on global amount of methylated cytosines (5-mC) in samples relative 
to global cytidine (5-mC + dC).
Wound-healing assay (Scratch test)
The cells were seeded into 16-well plate to reach confluence ~80%. After seeding a pin was 
used to a scratch and remove cells from a discrete area of the confluent monolayer to form a cell-free 
zone. After that, cells were treated with sarcosine (10 μM), DNA hypomethylating agent 5-azacytidine 
(5-Aza, 10 μM). After 6; 12 and 24 h, the micrographs of cells were taken using EVOS FL Auto Cell 
Imaging System and compared with micrographs obtained in 0 h, using TScratch software.
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Descriptive statistics
For the statistical evaluation of the results, the mean was taken as the measurement of the main 
tendency, while standard deviation was taken as the dispersion measurement. Differences between 
groups were analyzed using paired t-test. Unless noted otherwise, the threshold for significance was p
< 0.05. For analyses Software Statistica 12 (StatSoft, Tulsa, OK, USA) was employed.
RESULTS AND DISCUSSION
First, we focused on sarcosine stimulatory vs. inhibitory effects on enzymes involved 
in sarcosine metabolical pathway (GNMT, DMGDH, SARDH and PIPOX). Figure 1 illustrates 
representative immunofluorescence micrographs of sarcosine metabolism-related enzymes in prostate 
cells incubated without  or with sarcosine (10 µM) together with quantitation of expression of certain 
enzymes. The stimulatory effects were found for SARDH and PIPOX, which are mainly connected 
with sarcosine degradation. Hence, it is obvious that an exogenous addition of sarcosine results in its 
demethylation through sarcosine degradation pathway. Methyl groups can be further used 
for methylation of various acceptors such as DNA, RNA, etc., which is one of the major hallmarks 
of cancer development and progression (Suh et al. 2011).
Figure 1 (A) Representative IF micrographs andquantitation of IF of analysed enzymes. (B) IF images 
of LNCaP cells for SARDH expression after sarcosine treatment compared to control
We further focused on estimation of ratio between SAM and SAH. Figure 2 clearly shows 
that SAM/SAH ratio changed when compared control cells and cells treated with sarcosine. 
The highest SAM/SAH ratio was determined at LNCaP cells treated with sarcosine after 24 h 
of incubation. These findings indicate that SARDH/PIPOX degradation of sarcosine had significant 
stimulatory effects on a formation of methyl-donor SAM, which delivers free methyl groups 
to the target site (Shukeir et al. 2006). Simultaneously, we identified slight decrease in SAH, 
which indicate higher needs of prostate cells to maintain SAM activity for transferring 
the methyl groups.
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Figure 2 Values of SAM and SAH and their ratios in PNT1A, 22Rv1 and LNCaP cells non-
and supplemented with sarcosine 
With respect to the obtained data we analyzed global methylation profiles in all tested cells.
The highest level of global methylation was found in PNT1A after 72 h treatment (63.8%), 
which corresponds to the sarcosine-related induction of their proliferation and invassiveness 
investigated in our previous studies. Methyl groups coming from sarcosine can be used by DNA 
methyl transferase to methyation of DNA promotors. Overall, we show that sarcosine can efficiently 
provide free methyl group for DNA methylation processes.
Figure 3 Global methylation index of prostate cell lines treated with sarcosine
To determine whether sarcosine and 5-Aza treatment suppress cell migration was 
performed (Figure 4). The migration was stopped in the LNCaP by sarcosine treatment after 24 h. 
The migration was higher after sarcosine supplementation in all three cell lines. That indicate 
sarcosine as a potential donor of methy group, what can be used for methylation of regulatory 
genes. In non-malignant cell line PNT1A was not different in migration after 24 h supplementation 
by 5-Aza and combination of 5-Aza+Sarc. It highlights different metabolism of sarcosine 
in non-malignant cells and inhibition of methylation. In malignant cells (LNCaP and 22Rv1) 
after 24 h was proliferation slower in combinant treatment with 5-Aza+Sarc. Hypomethylation 
caused by 5-Aza probably inhibited methyl group transfer in malignant prostatic cells metaboslim 
connected with sarcosine metabolism. 
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Figure 4 (A) Representative IF images for DNMT1 ater treatment. (B) Sarcosine effect on migration 
of prostate cells
CONCLUSION
The mechanistically increased level of sarcosine stimulates expression of enzymes involved 
in its metabolism. Sarcosine can hence be utilized as efficient donor of methyl group. Aftervards 
the methyl groups can be transferred by DNMTs (DNA methl transferases) to promotor areas, 
which can be hypermethylated. This can result in abnormal transcription with subsequent alterations 
in cellular proliferation, cell cycle control, etc.
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